IDEAYA Biosciences Toekomstige groei

Future criteriumcontroles 2/6

IDEAYA Biosciences zal naar verwachting groeien in winst en omzet met respectievelijk 8.4% en 67% per jaar. De winst per aandeel zal naar verwachting groeien met 11.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -29.4% zijn.

Belangrijke informatie

8.4%

Groei van de winst

11.5%

Groei van de winst per aandeel

Biotechs winstgroei	28.0%
Inkomstengroei	67.0%
Toekomstig rendement op eigen vermogen	-29.4%
Dekking van analisten	Good
Laatst bijgewerkt	07 Nov 2024

Recente toekomstige groei-updates

Recent updates

Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

Nov 09

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Oct 03

IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans

Jul 04

We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Mar 10

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Nov 04

Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data

Oct 06

Ideaya Biosciences slides 8.5% aftermarket on $80M stock offering

Sep 14

Ideaya wins first milestone in GSK deal as cancer drug reaches clinical trials

Aug 29

Analysts Have Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Estimates By 6.2%

Aug 25

IDEAYA Biosciences GAAP EPS of -$0.57 misses by $0.05, revenue of $11.34M beats by $4.75M

Aug 15

IDEAYA, Amgen in clinical trial deal for small molecule cancer agent

Jul 27

Ideaya: Next 6 Months Critical For Precision Oncology Biotech

Jun 16

Winst- en omzetgroeiprognoses

NasdaqGS:IDYA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	54	-241	-256	-216	13
12/31/2025	17	-240	-233	-222	14
12/31/2024	3	-201	-123	-190	11
9/30/2024	4	-178	-153	-150	N/A
6/30/2024	12	-154	-134	-131	N/A
3/31/2024	16	-129	-135	-131	N/A
12/31/2023	23	-113	-118	-115	N/A
9/30/2023	23	-103	-116	-115	N/A
6/30/2023	45	-74	-111	-109	N/A
3/31/2023	47	-68	-98	-95	N/A
12/31/2022	51	-59	-91	-87	N/A
9/30/2022	50	-53	-85	-80	N/A
6/30/2022	29	-66	-72	-69	N/A
3/31/2022	32	-55	-64	-62	N/A
12/31/2021	28	-50	-58	-56	N/A
9/30/2021	36	-37	-53	-51	N/A
6/30/2021	36	-30	50	52	N/A
3/31/2021	27	-31	50	51	N/A
12/31/2020	20	-34	55	55	N/A
9/30/2020	9	-40	58	58	N/A
6/30/2020	N/A	-46	-43	-42	N/A
3/31/2020	N/A	-44	-40	-39	N/A
12/31/2019	N/A	-42	-41	-39	N/A
9/30/2019	N/A	-40	-40	-38	N/A
6/30/2019	N/A	-42	-39	-36	N/A
3/31/2019	N/A	-38	-34	-32	N/A
12/31/2018	N/A	-34	-29	-28	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat IDYA de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat IDYA de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat IDYA de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van IDYA ( 67% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van IDYA ( 67% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat IDYA binnen 3 jaar verliesgevend zal zijn.

IDEAYA Biosciences Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates fall by 32%

Consensus revenue estimates increase by 10%

Consensus revenue estimates fall by 28%

Price target increased by 12% to US$49.11

Price target increased by 8.2% to US$43.70

Price target increased by 7.7% to US$42.10

Recent updates

Third quarter 2024 earnings released: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023)

IDEAYA Biosciences, Inc. Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

IDEAYA Biosciences, Inc. Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success

IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel

Consensus revenue estimates fall by 32%

First half 2024 earnings released: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)

Consensus revenue estimates increase by 10%

IDEAYA Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $263.000016 million.

Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 3000E Value Index

Chief Legal Officer & Company Secretary exercised options to buy US$1.9m worth of stock.

IDEAYA Biosciences, Inc Announces Resignation of Jason Throne as Chief Legal Officer and Secretary, Effective July 11, 2024

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer

IDEAYA Biosciences, Inc. Announces Clinical Program Updates for Ide397 A Potential First-In-Class Phase 2 Mat2a Inhibitor Targeting MTAP-Deletion Solid Tumors

Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'

IDEAYA Biosciences, Inc. Announces Results for darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma At Asco and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study

Chief Scientific Officer notifies of intention to sell stock

IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024

President notifies of intention to sell stock

Consensus revenue estimates fall by 28%

First quarter 2024 earnings released: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)

IDEAYA Biosciences, Inc., Annual General Meeting, May 31, 2024

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?

Price target increased by 12% to US$49.11

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Ideaya Biosciences: A Strong Bet In Targeted Oncology

Principal Accounting Officer notifies of intention to sell stock

Price target increased by 8.2% to US$43.70

Co-Founder notifies of intention to sell stock

Price target increased by 7.7% to US$42.10

New major risk - Shareholder dilution

IDEAYA Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

IDEAYA Biosciences, Inc. Announces Resignation of Paul A. Stone as Chief Financial Officer

Chief Legal Officer & Company Secretary notifies of intention to sell stock

Consensus revenue estimates increase by 25%

Price target increased by 7.8% to US$35.08

IDEAYA Biosciences, Inc. Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo) Adjuvant Uveal Melanoma

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chief Legal Officer & Company Secretary notifies of intention to sell stock

IDEAYA Biosciences, Inc. Appoints Andres Ruiz Briseno as Principal Accounting Officer

IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans

New major risk - Shareholder dilution

IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types

Chief Legal Officer & Company Secretary exercised options and sold US$64k worth of stock

Chief Legal Officer & Company Secretary notifies of intention to sell stock

Consensus revenue estimates increase by 23%, EPS downgraded

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.1% to US$28.11

Co-Founder exercised options to buy US$160k worth of stock.

We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

IDEAYA Biosciences, Inc. Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma

IDEAYA Biosciences, Inc. Announces Board Appointments

IDEAYA Biosciences, Inc Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161

IDEAYA Biosciences, Inc. Appoints Darrin M. Beaupre as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline

Price target increased to US$23.38

Consensus revenue estimates increase by 85%

Price target increased to US$23.38

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations